AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-23. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Besides inhibiting human acetylcholinesterase (although to a lesser degree than the insect enzyme), carbamate insecticides also target human melatonin receptors. The human health effects of carbamates are well documented in the list of known endocrine disruptor compounds. Clinical effects of carbamate exposure can vary from slightly toxic to highly toxic depending on a variety of factors including such as dose and route of exposure with ingestion and inhalation resulting in the most rapid clinical effects. These clinical manifestations of carbamate intoxication are muscarinic signs, nicotinic signs, and in rare cases central nervous system signs.
== Function == The protein encoded by this gene is the predominant constituent of the crystalline core of the eosinophil granule. High levels of the proform of this protein are also present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT), and C3dg. This protein may be involved in antiparasitic defense mechanisms as a cytotoxin and helmintho-toxin, and in immune hypersensitivity reactions. It is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases. PRG2 is a 117-residue protein that predominates in eosinophil granules. It is a potent enzyme against helminths and is toxic towards bacteria and mammalian cells in vitro. The eosinophil major basic protein also causes the release of histamine from mast cells and basophils, and activates neutrophils and alveolar macrophages.
Kennedy left the Foster administration when he was elected Louisiana State Treasurer in 1999, having unseated incumbent Ken Duncan with 55.6% of the vote, or 621,796 votes, to Duncan's 44.4%, or 497,319 votes. Kennedy was reelected treasurer without opposition in 2003, 2007 and 2011. In 2015, he defeated his sole challenger with 80% of the vote.
Sources: en.wikipedia.org
=== In sport === The WADA has prohibited the use of tramadol in competition since 1 January 2024. Misuse of painkillers is up to four times more common among athletes compared to the general population. From March 2019, the Union Cycliste Internationale (UCI) banned the drug, after riders were using the painkiller to improve their performance. No significant improvements in performance were found when compared to placebo. In 2026 the International Go Federation (IGF) revoked Korean player Sa Woo Kim’s third place in the 2025 World Amateur Go Championship in Vancouver, Canada because he had tested positive for tramadol. The IGF adopted the World Anti-Doping Code in October 2020.
Mamadou Diallo Sory - Former minister of Justice Maman Sambo Sidikou - former Ambassador Nigerien to the United States, United Nations secretary-general's special representative for the Democratic Republic of the Congo and head of the U.N. peacekeeping mission there, MONUSCO, high representative of the African Union for Mali and the Sahel. Abdoulaye Diori Kadidiatou Ly - jurist, former president of the Constitutional Court of Niger. Abdou Sidikou - former minister of foreign affairs, Niger. Yaou Sangaré Bakary - former ambassador to China, Minister of Foreign Affairs. Bouli Ali Diallo - academic and activist, Niger. Achta Djibrine Sy former Minister of Commerce and Industry, Chad. Banata Tchale Sow - economist, former chief of staff, Chad. Hindou Oumarou Ibrahim- environmental activist and geographer. Coordinator Association of Peul Women and Autochthonous People of Chad (AFPAT) and Co-director Pavilion of World Indigenous People, Chad Mariam Boni Diallo - first female foreign minister, Benin Republic. Ali Darassa – leader of the Central African rebel group, the Union for Peace in the Central African Republic (UPC) a self-defense force. Al-Amin Abu-Manga, linguist and professor at the University of Khartoum Ali Mohamed Issah Salou Jules Hamidou Habib Habibou Hassan Diallo
=== Congenital heart defects === In some cases, critical congenital heart defects (CCHD) are not identified by prenatal ultrasound or postnatal physical examination. Pulse oximetry has been recently added as a bedside screening test for CCHD at 24 to 48 hours after birth. However, not all heart problems can be detected by this method, which relies only on blood oxygen levels. When a baby tests positive, urgent subsequent examination, such as echocardiography, is undergone to determine the cause of low oxygen levels. Babies diagnosed with CCHD are then seen by cardiologists.
Upon returning from questioning by the FBI, Eddie and Lily realize that they are being framed after encountering planted evidence in both of their houses. The two flee to an observatory in Wisconsin belonging to Maggie McDermott, an old friend of Eddie's. After resting up, they contact Paul but are almost caught and narrowly escape. As the pair are evading more police, Paul meets with Lyman Earl Collier at the C-Systems Research complex, where it is revealed that C-Systems orchestrated the plot to destroy the laboratory and frame the pair for it, with Lyman ordering the attack. Despite some disagreement, Paul and Lyman decide to continue hunting for the pair, a task facilitated when Eddie covertly arranges a meeting with Paul. At their rendezvous, Paul reveals his involvement in framing Eddie, but the meeting ends in an ambush in which Lyman's thugs Yusef Reed and Clancy Butler, who murdered Alistair, capture Lily while Eddie barely escapes. After tracing the license plate on the thugs' van, Eddie tracks them to the secret C-Systems Research facility where Paul and Lyman are forcing Lily and Chen to replicate the project. When C-Systems' test reactor malfunctions, Paul, the scientists and the prisoners all depart, allowing Eddie to furtively "fix" the system that night. The next morning, one of the other scientists discovers the working reactor and everyone celebrates. A suspicious Paul immediately obtains a download of the fusion data, and secretly gives it to his assistant, Anita, for safekeeping.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.